| __timestamp | MannKind Corporation | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 5078000000 |
| Thursday, January 1, 2015 | 108402000 | 4717000000 |
| Friday, January 1, 2016 | 46928000 | 5096000000 |
| Sunday, January 1, 2017 | 74959000 | 4986000000 |
| Monday, January 1, 2018 | 79716000 | 4214000000 |
| Tuesday, January 1, 2019 | 74669000 | 3806000000 |
| Wednesday, January 1, 2020 | 59040000 | 3671000000 |
| Friday, January 1, 2021 | 77417000 | 3528000000 |
| Saturday, January 1, 2022 | 91473000 | 3445000000 |
| Sunday, January 1, 2023 | 94314000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and MannKind Corporation from 2014 to 2023. Over this period, Teva's SG&A expenses have seen a significant decline, dropping from approximately $5 billion in 2014 to around $3.5 billion in 2023, reflecting a strategic reduction of about 30%. In contrast, MannKind's expenses have remained relatively stable, with a slight increase of about 20% from $79 million to $94 million. This divergence highlights Teva's aggressive cost-cutting measures, while MannKind maintains a steady approach. Understanding these trends offers valuable insights into each company's operational strategies and financial health, providing a window into their future trajectories in a competitive market.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited and Viatris Inc.: SG&A Spending Patterns Compared
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs MannKind Corporation
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared